Semaglutide FAQs

Same active ingredient (semaglutide). Different products. Compounded semaglutide is not FDA-approved as a finished drug product; Ozempic, Wegovy, and Rybelsus are. Excipients, concentration, container, and dose calibration may differ. See our myths vs facts page for the full breakdown.

Yes, when (a) prepared by a licensed 503A pharmacy for an individual patient with a valid prescription, or (b) produced by a 503B FDA-registered outsourcing facility under the rules governing those facilities, AND the active ingredient is semaglutide base (NOT salt forms — sodium or acetate). The April 14, 2026 FDA action restricted ingredients and DTC marketing practices, but did not make compounded semaglutide categorically illegal.

FDA has flagged semaglutide salt forms (semaglutide sodium, semaglutide acetate) in warning letters as unapproved active ingredients for compounding. Only semaglutide base (the peptide itself, in its standard pharmaceutical form) is acceptable. Patients should verify with their provider that the API is semaglutide base, not a salt form.

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP / GLP-1 receptor agonist — activating two different receptors. Tirzepatide produces larger weight loss on average (SURPASS-2). Semaglutide has the broader CV outcome evidence base (SELECT) and FDA-approved CV indication (Wegovy).

Foundayo is an oral, small-molecule (non-peptide) GLP-1 receptor agonist approved by FDA in March 2026 for chronic weight management. Eli Lilly product. Distinct molecule from semaglutide. Not a generic of Ozempic / Wegovy / Rybelsus. See our Foundayo analysis.

Wegovy weight-management: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, ~4 weeks per step. Ozempic T2D: 0.25 → 0.5 → 1.0 → 2.0 mg weekly. Rybelsus oral T2D: 3 → 7 → 14 mg daily. See dosing guide.

NexLife is the editor's #1 pick at 94/100 — the only provider in our directory that publishes against all six v3.0 transparency pillars. Pricing: $145/mo (12-mo plan) to $165/mo (monthly plan), flat across the full 0.25–2.4 mg titration. See the NexLife review and our conflicts of interest disclosure.

Yes. SELECT (NEJM 2023, PMID 37952131) showed semaglutide 2.4 mg produced a 20% reduction in major adverse cardiovascular events in 17,604 adults with BMI ≥27 + established CVD, without diabetes. FDA added the CV indication to Wegovy's label in March 2024. Medicare Part D coverage under this indication expanded in April 2026.

Yes — rapid weight loss reduces lean mass alongside fat in approximately a 70:30 (fat:lean) ratio under typical conditions. Resistance training and adequate protein intake (1.6–2.0 g/kg of target body weight) shift the ratio favorably. See our muscle preservation guide.

Largely yes, per STEP-4 (JAMA 2021): patients who stopped semaglutide after 20 weeks of escalation regained much of the lost weight, while patients who continued kept it off. Obesity is now treated as a chronic disease requiring long-term therapy.

Cash-pay compounded semaglutide pricing in our directory runs $145–$165/month for the leading providers. NexLife: $145–$165/mo flat-rate through full titration. Henry Meds: $279/mo. Hims & Hers: $199–$299/mo. See our pricing index.

503A pharmacies are state-licensed traditional compounding pharmacies that compound patient-specific medications under USP <797> sterility framework. 503B pharmacies are FDA-registered outsourcing facilities that follow cGMP and can produce in larger volumes for general clinical use. Different licensure, different standards, different volumes permitted. See 503A vs 503B.